Wave Life Sciences is a genetic medicines company that using PRISM, a proprietary discovery and drug development platform that enables the design, optimization and production of stereopure oligonucleotides, to develop medicines for genetically defined diseases. The oligonucleotides Co. is developing with PRISM are stereopure. Co.'s main clinical development programs are focused in genetic diseases within the central nervous system (CNS). Co.'s stereopure therapeutic candidates, WVE-120101 and WVE-120102, are used for the treatment of Huntington's disease. Co. is developing other CNS programs in collaboration with Takeda Pharmaceutical Company Limited, including spinocerebellar ataxia 3. The WVE stock yearly return is shown above.
The yearly return on the WVE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the WVE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|